Search results
Results from the WOW.Com Content Network
That said, NTLA-2001 and NTLA-2002, even if approved, won't capture this entire space by themselves. ... Intellia Therapeutics won't get a boost to its stock price anywhere close to what Wall ...
Price Action: NTLA stock is down 12.7% at $10.49 at last check Friday. Read Next: Salesforce Launches Retail Cloud And Agentforce Solutions: Details. Image via Shutterstock.
In this article you are going to find out whether hedge funds think Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a good investment right now. We like to check what the smart money thinks first ...
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
To get to a market cap of $1 trillion, I think it needs to generate at least $25 billion in net income, which would give the stock a price-to-earnings ratio of 40 at a trillion-dollar market cap ...
The average price target is $215.52, which means that the average Tesla stock forecast calls for shares to reach $215.52 by Oct. 27, 2024. What Will Tesla’s Stock Price Be in 2025?
First, investors should realize that taking a $205 billion market cap to $1 trillion in six years will require an average stock price increase of 30% annually for the next six years.
The stock trades at a price-to-earnings ratio of 53 -- truly a nosebleed valuation. Shares have not been this expensive since 1999. Shares have not been this expensive since 1999.